Immune cell therapy shows promise for tough lupus cases

NCT ID NCT06265220

First seen Dec 17, 2025 · Last updated May 09, 2026 · Updated 16 times

Summary

This early-stage study tests a new treatment called AB-101, made from natural killer cells, combined with antibody therapy for people with lupus nephritis or other hard-to-treat lupus. The goal is to see if it is safe and can help when standard treatments have failed. About 51 adults will receive up to two cycles of the therapy and be monitored for side effects and response.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SLE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Artiva Investigational Site Aventura

    Aventura, Florida, 33180, United States

  • Artiva Investigational Site Birmingham

    Birmingham, Alabama, 35249, United States

  • Artiva Investigational Site Charlotte

    Charlotte, North Carolina, 28625, United States

  • Artiva Investigational Site Iowa

    Iowa City, Iowa, 52242, United States

  • Artiva Investigational Site Mesquite

    Mesquite, Texas, 75150, United States

  • Artiva Investigational Site Plantation

    Plantation, Florida, 33324, United States

  • Artiva Investigational Site San Diego

    San Diego, California, 92121, United States

  • Artiva Investigational Site Tucson

    Tucson, Arizona, 85724, United States

  • Artiva Investigational Site Woodlands

    The Woodlands, Texas, 77382, United States

Conditions

Explore the condition pages connected to this study.